Executive Summary

For CRISPR-Cas9 based therapeutics, demonstrating precise on-target editing is a foundational component of any successful IND submission. Moving beyond simple sequence verification requires the development of quantitative, mechanism-of-action (MoA) reflective cell-based assays. These assays provide definitive evidence of the intended biological consequence of the gene edit, directly measuring functional protein restoration or transcript modification. A robust analytical strategy for quantifying potency is a foundational requirement for minimizing clinical risk and aligning with global regulatory expectations.

Frequently Asked Questions

Transitioning from Edit Confirmation to Functional Quantification

Confirmation of a successful gene edit at the DNA level is an initial data point, but it is insufficient for an IND filing without functional quantification. The central challenge is to develop and validate assays that quantitatively measure the intended biological effect of that edit. A scientifically rigorous preclinical strategy must be tailored to the asset’s specific modality and target indication, linking the molecular event to a functional, measurable outcome.

This principle is demonstrated in therapeutic approaches for conditions like Angelman syndrome. The strategic goal is to prove that the molecular intervention functionally unsilences the paternal allele and restores protein expression in the correct neuronal populations (PMID: 33411694). This focus on translational impact, which moves beyond confirming an edit to an antisense transcript, defines a program’s readiness for clinical evaluation.

Core Methodologies for Cell-Based Potency Assays

A multi-faceted approach is required to build a comprehensive data package that characterizes the potency of a CRISPR-Cas9 therapeutic. The selection of methods is dictated by the specific mechanism of action.

• Flow Cytometry: Provides quantitative, single-cell resolution data on target protein expression, ideal for therapies designed to restore a cell-surface or intracellular protein.

• ELISA / Western Blot: Measures changes in total protein levels in cell lysates or secreted proteins in culture media, offering a direct assessment of functional protein restoration.

• Reporter Gene Assays: Can be engineered to measure the activity of a specific pathway that is modulated by the gene editing event.

• Enzyme Activity Assays: For therapies targeting enzymes, direct measurement of substrate turnover provides a highly relevant functional readout.

These clinical-grade assay development activities are conducted within our extensive >100,000 sq ft facility

, ensuring that analytical development and preclinical testing occur in a coordinated environment.

A Data-Driven Path to IND

The data generated from these quantitative cell-based assays forms a central component of the CMC section of an IND. When combined with robust analytics for gRNA specificity and comprehensive off-target analysis, this package provides regulators with a clear understanding of the therapeutic’s activity and specificity. This integrated approach to analytics is a key factor in the 100% successful IND rate achieved by our core scientific leadership since 2019, a track record established prior to the formal launch of Franklin Biolabs in 2024.

Our focus is on creating a direct, data-driven line from vector analytics to a successful regulatory submission, accelerating typical timelines to get candidates to IND in 18-24 months. For more information on our comprehensive analytical capabilities, please see our core Vector | CMC | Analytics Services offerings.